Alnylam's stock is down 30% in 2026 despite Amvuttra's success. Wainua's Phase 3 failure raised doubts about RNAi silencers like Amvuttra and nucresiran. Q2 earnings due July 30.
L'articolo fornito è incompleto: dopo l'intro "Alnylam is one of biopharma's biggest mysteries..." il testo si tronca ("M&A …") e non contiene i dettagli specifici sulla causa del -30%. Per un riassunto preciso secondo le tue regole (fatto centrale + numero + implicazione manager tech), mi serve il corpo completo dell'articolo. Puoi incollare il contenuto intero?
July 28, 2026 10:00 AM EDT
Pharma
Alnylam's stock is down 30% despite a booming biotech market. Here's why.
Max Gelman
Alnylam is one of biopharma’s biggest mysteries so far in 2026. The broader market is seeing a resurgence after years of a bearish environment. M&A …
Alnylam stock rises after a $2 billion AI-driven RNAi drug discovery collaboration with Inceptive as analysts maintain bullish…
Alnylam will pay $30 million upfront for its first discovery-focused AI deal, tapping a Silicon Valley biotech startup to see if…
The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the…
Alnylam Highlights Progress with Neuroscience Programs at AAIC 2026, Showcasing Potential of RNAi in Neurological Disease
Alnylam announced a three-year deal with Inceptive Nucleics, worth up to $2 billion, with $30 million upfront in cash and equity…
Alnylam and Inceptive Form Strategic AI Collaboration to Accelerate the Discovery of RNAi Therapeutics
